{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T22:26:38Z","timestamp":1788560798578,"version":"build-2803163510"},"reference-count":82,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T00:00:00Z","timestamp":1706659200000},"content-version":"am","delay-in-days":395,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.neurol.2022.11.005","type":"journal-article","created":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T07:25:11Z","timestamp":1670829911000},"page":"90-105","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Gene therapy review: Duchenne muscular dystrophy case study"],"prefix":"10.1016","volume":"179","author":[{"given":"E.","family":"Berling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Nicolle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Lafor\u00eat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Ronzitti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurol.2022.11.005_bib0415","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/nrd.2018.110","article-title":"Gene therapy for neurological disorders: progress and prospects","volume":"17","author":"Deverman","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.neurol.2022.11.005_bib0420","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0140-6736(21)02017-1","article-title":"Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1\/2 trial and expanded access","volume":"399","author":"Fumagalli","year":"2022","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.neurol.2022.11.005_bib0425","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2022.11.005_bib0430","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1056\/NEJMoa1700554","article-title":"Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy","volume":"377","author":"Eichler","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2022.11.005_bib0435","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2022.11.005_bib0440","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2022.11.005_bib0445","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.ophtha.2020.12.012","article-title":"Efficacy and safety of intravitreal gene therapy for leber hereditary optic neuropathy treated within 6 months of disease onset","volume":"128","author":"Newman","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.neurol.2022.11.005_bib0450","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus Sham control in later-onset spinal muscular atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2022.11.005_bib0455","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Day","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2022.11.005_bib0460","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1093\/hmg\/2.6.717","article-title":"Direct retroviral-mediated transfer of a dystrophin minigene into mdx mouse muscle in vivo","volume":"2","author":"Dunckley","year":"1993","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.neurol.2022.11.005_bib0465","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/humu.22758","article-title":"The TREAT-NMD DMD global database: analysis of more than 7000 Duchenne muscular dystrophy mutations","volume":"36","author":"Bladen","year":"2015","journal-title":"Hum Mutat"},{"key":"10.1016\/j.neurol.2022.11.005_bib0470","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1038\/s41467-018-03910-9","article-title":"Medical relevance of protein-truncating variants across 337,205 individuals in the UK Biobank study","volume":"9","author":"DeBoever","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.neurol.2022.11.005_bib0475","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1242\/jcs.181008","article-title":"Nonsense-mediated mRNA decay in humans at a glance","volume":"129","author":"Kurosaki","year":"2016","journal-title":"J Cell Sci"},{"key":"10.1016\/j.neurol.2022.11.005_bib0480","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1242\/dmm.018424","article-title":"Animal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapy","volume":"8","author":"McGreevy","year":"2015","journal-title":"Dis Model Mech"},{"key":"10.1016\/j.neurol.2022.11.005_bib0485","doi-asserted-by":"crossref","first-page":"100877","DOI":"10.1016\/j.spen.2021.100877","article-title":"Therapeutic approaches for Duchenne muscular dystrophy: old and new","volume":"37","author":"Mackenzie","year":"2021","journal-title":"Semin Pediatr Neurol"},{"key":"10.1016\/j.neurol.2022.11.005_bib0490","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1089\/hum.2015.107","article-title":"Perspective on adeno-associated virus capsid modification for Duchenne muscular dystrophy gene therapy","volume":"26","author":"Nance","year":"2015","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.neurol.2022.11.005_bib0495","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/343180a0","article-title":"Very mild muscular dystrophy associated with the deletion of 46% of dystrophin","volume":"343","author":"England","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.neurol.2022.11.005_bib0500","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1016\/j.ymthe.2018.07.011","article-title":"Micro-dystrophin gene therapy for Duchenne muscular dystrophy","volume":"26","author":"Duan","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurol.2022.11.005_bib0505","doi-asserted-by":"crossref","first-page":"S303","DOI":"10.3233\/JND-210678","article-title":"Gene therapy for Duchenne muscular dystrophy","volume":"8","author":"Elangkovan","year":"2021","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.neurol.2022.11.005_bib0510","unstructured":"Mendell JR, Sahenk Z, Lehman KJ, Lowes LP, Reash NF, Alfano LN, et al. Phase 1\/2a trial of delandistrogene moxeparvovec in patients with DMD: 4-year update n.d.:13. https:\/\/investorrelations.sarepta.com\/static-files\/b42b4431-74c7-4b90-9232-f36a05d91874. Unpublished results."},{"key":"10.1016\/j.neurol.2022.11.005_bib0515","doi-asserted-by":"crossref","unstructured":"Roxana Dreghici. IGNITE DMD Phase I\/II Study of SGT-001 Microdystrophin Gene Therapy for DMD: 2-Year Outcomes Update. MDA Clin Sci Conf 2022 n.d. https:\/\/www.mdaconference.org\/abstract-library\/ignite-dmd-phase-i-ii-study-of-sgt-001-microdystrophin-gene-therapy-for-dmd-2-year-outcomes-update\/. Unpublished results.","DOI":"10.1016\/j.nmd.2022.07.234"},{"key":"10.1016\/j.neurol.2022.11.005_bib0520","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1001\/jamaneurol.2020.1484","article-title":"Assessment of systemic delivery of rAAVrh74.MHCK7.micro-dystrophin in children with duchenne muscular dystrophy: a nonrandomized controlled trial","volume":"77","author":"Mendell","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurol.2022.11.005_bib0525","first-page":"S101","article-title":"One-year data from ENDEAVOR, a phase 1b trial of delandistrogene moxeparvovec in boys with DMD","volume":"32","author":"Zaidman","year":"2022","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.neurol.2022.11.005_bib0530","unstructured":"Q2 2022 Business Update and Financial Results n.d. https:\/\/investors.solidbio.com\/static-files\/3b073d68-384d-430b-a40b-e7bfc50d4bc0. Unpublished results."},{"key":"10.1016\/j.neurol.2022.11.005_bib0535","unstructured":"Solid Biosciences Announces FDA Lifts Clinical Hold on IGNITE DMD Clinical Trial. Solid Biosci n.d. https:\/\/www.solidbio.com\/about\/media\/press-releases\/solid-biosciences-announces-fda-lifts-clinical-hold-on-ignite-dmd-clinical-trial. Unpublished results."},{"key":"10.1016\/j.neurol.2022.11.005_bib0540","unstructured":"Butterfield R. One year data from ambulatory boys in a phase 1b, open-label study of fordadistrogene movaparvovec (PF-06939926) for Duchenne muscular dystrophy (DMD). MDA Clin Sci Conf 2022 n.d. https:\/\/www.mdaconference.org\/abstract-library\/one-year-data-from-ambulatory-boys-in-a-phase-1b-open-label-study-of-fordadistrogene-movaparvovec-pf-06939926-for-duchenne-muscular-dystrophy-dmd\/. Unpublished results."},{"key":"10.1016\/j.neurol.2022.11.005_bib0545","doi-asserted-by":"crossref","unstructured":"Philippidis A. After Patient Death, FDA Places Hold on Pfizer DMD Gene Therapy Trial. GEN - Genet Eng Biotechnol News 2021. https:\/\/www.genengnews.com\/topics\/genome-editing\/gene-therapy\/after-patient-death-fda-places-hold-on-pfizer-dmd-gene-therapy-trial\/. Unpublished results.","DOI":"10.1089\/hum.2022.29198.bfs"},{"key":"10.1016\/j.neurol.2022.11.005_bib0550","unstructured":"Bonnemann C. A collaborative analysis by clinical trial sponsors and academic experts of anti-transgene SAEs in studies of gene therapy for DMD. MDA Clin Sci Conf 2022 n.d. https:\/\/www.mdaconference.org\/abstract-library\/a-collaborative-analysis-by-clinical-trial-sponsors-and-academic-experts-of-anti-transgene-saes-in-studies-of-gene-therapy-for-dmd\/. Unpublished results."},{"key":"10.1016\/j.neurol.2022.11.005_bib0555","article-title":"Development of therapeutic RNA manipulation for muscular dystrophy","volume":"4:863651","author":"Saifullah","year":"2022","journal-title":"Front Genome Ed"},{"key":"10.1016\/j.neurol.2022.11.005_bib0560","doi-asserted-by":"crossref","unstructured":"Azad MTA, Qulsum U, Tsukahara T. Comparative Activity of Adenosine Deaminase Acting on RNA (ADARs) Isoforms for Correction of Genetic Code in Gene Therapy. Curr Gene Ther 2019.;19:31-9.","DOI":"10.2174\/1566523218666181114122116"},{"issue":"3","key":"10.1016\/j.neurol.2022.11.005_bib0565","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/s41592-019-0323-0","article-title":"In vivo RNA editing of point mutations via RNA-guided adenosine deaminases","volume":"16","author":"Katrekar","year":"2019","journal-title":"Nat Methods"},{"key":"10.1016\/j.neurol.2022.11.005_bib0570","doi-asserted-by":"crossref","first-page":"4943","DOI":"10.3390\/ijms21144943","article-title":"Development of a single construct system for site-directed RNA editing using MS2-ADAR","volume":"21","author":"Tohama","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.neurol.2022.11.005_bib0575","doi-asserted-by":"crossref","first-page":"109851","DOI":"10.1016\/j.enzmictec.2021.109851","article-title":"Double MS2 guided restoration of genetic code in amber (TAG), opal (TGA) and ochre (TAA) stop codon","volume":"149","author":"Bhakta","year":"2021","journal-title":"Enzyme Microb Technol"},{"key":"10.1016\/j.neurol.2022.11.005_bib0580","doi-asserted-by":"crossref","first-page":"17304","DOI":"10.1038\/s41598-020-74374-5","article-title":"RNA editing of BFP, a point mutant of GFP, using artificial APOBEC1 deaminase to restore the genetic code","volume":"10","author":"Bhakta","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.neurol.2022.11.005_bib0585","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/s41551-021-00774-1","article-title":"Restoration of dystrophin expression in mice by suppressing a nonsense mutation through the incorporation of unnatural amino acids","volume":"6","author":"Shi","year":"2022","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.neurol.2022.11.005_bib0590","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1177\/0883073810371129","article-title":"Read-Through Strategies For Suppression Of Nonsense Mutations In Duchenne\/Becker Muscular Dystrophy: Aminoglycosides and Ataluren (PTC124)","volume":"25","author":"Finkel","year":"2010","journal-title":"J Child Neurol"},{"key":"10.1016\/j.neurol.2022.11.005_bib0595","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1080\/13543784.2021.1868434","article-title":"therapeutics: a review of the effectiveness of small molecules, stop-codon readthrough, dystrophin gene replacement, and exon-skipping therapies","volume":"30","author":"Sheikh","year":"2021","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.neurol.2022.11.005_bib0600","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nature05756","article-title":"PTC124 targets genetic disorders caused by nonsense mutations","volume":"447","author":"Welch","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.neurol.2022.11.005_bib0605","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/mus.24332","article-title":"Ataluren treatment of patients with nonsense mutation dystrophinopathy","volume":"50","author":"Bushby","year":"2014","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.neurol.2022.11.005_bib0610","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S0140-6736(17)31611-2","article-title":"Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"McDonald","year":"2017","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.neurol.2022.11.005_bib0615","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.omtn.2017.06.013","article-title":"Efficacy and safety profile of Tricyclo-DNA antisense oligonucleotides in Duchenne muscular dystrophy mouse model","volume":"8","author":"Relizani","year":"2017","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.neurol.2022.11.005_bib0620","unstructured":"2\u2032-O-Methyl RNA\/Ethylene-Bridged Nucleic Acid Chimera Antisense Oligonucleotides to Induce Dystrophin Exon 45 Skipping - PubMed n.d. https:\/\/pubmed.ncbi.nlm.nih.gov\/28208626\/ (accessed October 13, 2022)."},{"key":"10.1016\/j.neurol.2022.11.005_bib0625","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1016\/j.ymthe.2017.07.014","article-title":"Quantitative antisense screening and optimization for Exon 51 Skipping in Duchenne muscular dystrophy","volume":"25","author":"Echigoya","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurol.2022.11.005_bib0630","doi-asserted-by":"crossref","first-page":"989","DOI":"10.3233\/JND-210643","article-title":"Open-label evaluation of eteplirsen in patients with Duchenne muscular dystrophy amenable to Exon 51 Skipping: PROMOVI Trial","volume":"8","author":"McDonald","year":"2021","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.neurol.2022.11.005_bib0635","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3233\/JND-210665","article-title":"A combined prospective and retrospective comparison of long-term functional outcomes suggests delayed loss of ambulation and pulmonary decline with long-term Eteplirsen treatment","volume":"9","author":"Mitelman","year":"2022","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.neurol.2022.11.005_bib0640","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/mus.27347","article-title":"Safety, tolerability, and pharmacokinetics of casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping: a randomized, double-blind, placebo-controlled, dose-titration trial","volume":"64","author":"Wagner","year":"2021","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.neurol.2022.11.005_bib0645","doi-asserted-by":"crossref","first-page":"e2270","DOI":"10.1212\/WNL.0000000000009233","article-title":"Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy","volume":"94","author":"Frank","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2022.11.005_bib0650","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1001\/jamaneurol.2020.1264","article-title":"Safety, tolerability, and efficacy of viltolarsen in boys with Duchenne muscular dystrophy amenable to Exon 53 skipping: a phase 2 randomized clinical trial","volume":"77","author":"Clemens","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurol.2022.11.005_bib0655","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1172\/JCI125228","article-title":"Selective tissue targeting of synthetic nucleic acid drugs","volume":"129","author":"Seth","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1016\/j.neurol.2022.11.005_bib0660","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/j.ymthe.2019.07.012","article-title":"Exons 45-55 skipping using mutation-tailored cocktails of antisense morpholinos in the DMD gene","volume":"27","author":"Echigoya","year":"2019","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurol.2022.11.005_bib0665","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1021\/acssynbio.0c00083","article-title":"Meganuclease-based artificial transcription factors","volume":"9","author":"Suzuki","year":"2020","journal-title":"ACS Synth Biol"},{"key":"10.1016\/j.neurol.2022.11.005_bib0670","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/nrg2842","article-title":"Genome editing with engineered zinc finger nucleases","volume":"11","author":"Urnov","year":"2010","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.neurol.2022.11.005_bib0675","series-title":"Transgenic Ascidians","article-title":"TALEN-Based Knockout System","author":"Yoshida","year":"2018"},{"key":"10.1016\/j.neurol.2022.11.005_bib0680","doi-asserted-by":"crossref","first-page":"37051","DOI":"10.1038\/srep37051","article-title":"Adenoviral vectors encoding CRISPR\/Cas9 multiplexes rescue dystrophin synthesis in unselected populations of DMD muscle cells","volume":"6","author":"Maggio","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.neurol.2022.11.005_bib0685","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nrm.2017.48","article-title":"end joining and alternative pathways to double-strand break repair","volume":"18","author":"Chang","year":"2017","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.neurol.2022.11.005_bib0690","doi-asserted-by":"crossref","first-page":"a012740","DOI":"10.1101\/cshperspect.a012740","article-title":"Repair of strand breaks by homologous recombination","volume":"5","author":"Jasin","year":"2013","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.neurol.2022.11.005_bib0695","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/(SICI)1097-4598(199801)21:1<91::AID-MUS12>3.0.CO;2-3","article-title":"Transplantation of myoblasts from a transgenic mouse overexpressing dystrophin produced only a relatively small increase of dystrophin-positive membrane","volume":"21","author":"Kinoshita","year":"1998","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.neurol.2022.11.005_bib0700","doi-asserted-by":"crossref","first-page":"e15286","DOI":"10.1371\/journal.pone.0015286","article-title":"Marginal level dystrophin expression improves clinical outcome in a strain of dystrophin\/utrophin double knockout mice","volume":"5","author":"Li","year":"2010","journal-title":"PLOS ONE"},{"key":"10.1016\/j.neurol.2022.11.005_bib0705","unstructured":"Huang S. Using CRISPR\/Cas9 nickase as a novel approach to correct large duplications in DMD. MDA Clin Sci Conf 2022 n.d."},{"key":"10.1016\/j.neurol.2022.11.005_bib0710","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/jgm.1611","article-title":"Endonucleases: tools to correct the dystrophin gene","volume":"13","author":"Rousseau","year":"2011","journal-title":"J Gene Med"},{"key":"10.1016\/j.neurol.2022.11.005_bib0715","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/0888-7543(88)90113-9","article-title":"An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus","volume":"2","author":"Monaco","year":"1988","journal-title":"Genomics"},{"key":"10.1016\/j.neurol.2022.11.005_bib0720","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.stemcr.2014.10.013","article-title":"Precise correction of the dystrophin gene in duchenne muscular dystrophy patient induced pluripotent stem cells by TALEN and CRISPR-Cas9","volume":"4","author":"Li","year":"2015","journal-title":"Stem Cell Rep"},{"key":"10.1016\/j.neurol.2022.11.005_bib0725","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/mt.2014.234","article-title":"Correction of dystrophin expression in cells from Duchenne muscular dystrophy patients through genomic excision of exon 51 by zinc finger nucleases","volume":"23","author":"Ousterout","year":"2015","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"10.1016\/j.neurol.2022.11.005_bib0730","doi-asserted-by":"crossref","first-page":"9176","DOI":"10.3390\/ijms23169176","article-title":"Full-length dystrophin restoration via targeted exon addition in DMD-patient specific iPSCs and cardiomyocytes","volume":"23","author":"Xiao","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.neurol.2022.11.005_bib0735","doi-asserted-by":"crossref","first-page":"7761","DOI":"10.1093\/nar\/gkac567","article-title":"Large-scale genome editing based on high-capacity adenovectors and\u00a0CRISPR-Cas9 nucleases rescues full-length dystrophin synthesis in DMD muscle cells","volume":"50","author":"Tasca","year":"2022","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.neurol.2022.11.005_bib0740","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00439-019-02107-4","article-title":"Exon skipping induced by nonsense\/frameshift mutations in DMD gene results in Becker muscular dystrophy","volume":"139","author":"Okubo","year":"2020","journal-title":"Hum Genet"},{"key":"10.1016\/j.neurol.2022.11.005_bib0745","doi-asserted-by":"crossref","first-page":"10524","DOI":"10.1074\/jbc.TM118.000372","article-title":"Homologous recombination and the repair of DNA double-strand breaks","volume":"293","author":"Wright","year":"2018","journal-title":"J Biol Chem"},{"key":"10.1016\/j.neurol.2022.11.005_bib0750","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1089\/hum.2013.081","article-title":"Gene correction of a duchenne muscular dystrophy mutation by meganuclease-enhanced exon knock-in","volume":"24","author":"Popplewell","year":"2013","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.neurol.2022.11.005_bib0755","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1146\/annurev-med-081117-010451","article-title":"CRISPR correction of Duchenne muscular dystrophy","volume":"70","author":"Min","year":"2019","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.neurol.2022.11.005_bib0760","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.omtm.2022.09.005","article-title":"Preclinical model for phenotypic correction of dystrophic epidermolysis bullosa by in\u00a0vivo CRISPR-Cas9 delivery using adenoviral vectors","volume":"27","author":"Garc\u00eda","year":"2022","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.neurol.2022.11.005_bib0765","doi-asserted-by":"crossref","first-page":"102935","DOI":"10.1016\/j.scr.2022.102935","article-title":"Generation of CD16A gene knockout human embryonic stem cell line using CRISPR\/Cas9","volume":"64","author":"Wu","year":"2022","journal-title":"Stem Cell Res"},{"key":"10.1016\/j.neurol.2022.11.005_bib0770","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1056\/NEJMoa1300662","article-title":"Gene editing of CCR5 in autologous CD4T cells of persons infected with HIV","volume":"370","author":"Tebas","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2022.11.005_bib0775","doi-asserted-by":"crossref","first-page":"6244","DOI":"10.1038\/ncomms7244","article-title":"Multiplex CRISPR\/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy","volume":"6","author":"Ousterout","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.neurol.2022.11.005_bib0780","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1126\/science.aad5177","article-title":"In vivo gene editing in dystrophic mouse muscle and muscle stem cells","volume":"351","author":"Tabebordbar","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.neurol.2022.11.005_bib0785","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.stem.2016.01.021","article-title":"A single CRISPR-Cas9 deletion strategy that targets the majority of dmd patients restores dystrophin function in hiPSC-derived muscle cells","volume":"18","author":"Young","year":"2016","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.neurol.2022.11.005_bib0790","doi-asserted-by":"crossref","first-page":"eaap9004","DOI":"10.1126\/sciadv.aap9004","article-title":"Correction of diverse muscular dystrophy mutations in human engineered heart muscle by single-site genome editing","volume":"4","author":"Long","year":"2018","journal-title":"Sci Adv"},{"key":"10.1016\/j.neurol.2022.11.005_bib0795","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/nbt.4148","article-title":"Adenine base editing in mouse embryos and an adult mouse model of Duchenne muscular dystrophy","volume":"36","author":"Ryu","year":"2018","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.neurol.2022.11.005_bib0800","doi-asserted-by":"crossref","first-page":"973326","DOI":"10.3389\/fbioe.2022.973326","article-title":"Delivering the CRISPR\/Cas9 system for engineering gene therapies: recent cargo and delivery approaches for clinical translation","volume":"10","author":"Foley","year":"2022","journal-title":"Front Bioeng Biotechnol"},{"key":"10.1016\/j.neurol.2022.11.005_bib0805","first-page":"1","article-title":"Current updates of CRISPR\/Cas9-mediated genome editing and targeting within tumor cells: an innovative strategy of cancer management","author":"Allemailem","year":"2022","journal-title":"Cancer Commun Lond Engl"},{"key":"10.1016\/j.neurol.2022.11.005_bib0810","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/nbt.2623","article-title":"High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells","volume":"31","author":"Fu","year":"2013","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.neurol.2022.11.005_bib0815","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1101\/gr.162339.113","article-title":"Analysis of off-target effects of CRISPR\/Cas-derived RNA-guided endonucleases and nickases","volume":"24","author":"Cho","year":"2014","journal-title":"Genome Res"},{"key":"10.1016\/j.neurol.2022.11.005_bib0820","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/nbt.2647","article-title":"DNA targeting specificity of RNA-guided Cas9 nucleases","volume":"31","author":"Hsu","year":"2013","journal-title":"Nat Biotechnol"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378722008414?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378722008414?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T05:46:27Z","timestamp":1758519987000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378722008414"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":82,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S0035378722008414"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2022.11.005","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gene therapy review: Duchenne muscular dystrophy case study","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2022.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}